How inherited cancer risks can be used for effective personalized therapy
Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...
MedPage Today3d
Survival Benefit in Metastatic CRPC Study Spurs Questions on Patient Selection
In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...
News-Medical.Net on MSN1d
Study uncovers protective mechanism of BRCA2 in cancer treatment
Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Advances in diagnostic pathology pave way for personalised cancer therapy in women
Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...
Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
Targeted Oncology2d
Expanding HRD and BRCA1/2 Testing Could Improve Access to Effective Treatments in Ovarian and Breast Cancer
A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients
Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...